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Abstract Some 30% of acute myeloid leukemia (AML)
patients display an internal tandem duplication (ITD)
mutation in the FMS-like tyrosine kinase 3 (FLT3) gene.
FLT3-ITDs are known to drive hematopoietic stem cells
towards FLT3 ligand independent growth, but the effects on
dendritic cell (DC) differentiation during leukemogenesis
are not clear. We compared the frequency of cells with
immunophenotype of myeloid DC (mDC: Lin
−, HLA-DR
+,
CD11c
+, CD86
+) and plasmacytoid DC (pDC: Lin
−, HLA-
DR
+, CD123
+, CD86
+) in diagnostic samples of 47 FLT3-
ITD
− and 40 FLT3-ITD
+ AML patients. The majority of
ITD
+ AML samples showed high frequencies of mDCs or
pDCs, with significantly decreased HLA-DR expression
compared with DCs detectable in ITD
− AML samples.
Interestingly, mDCs and pDCs sorted out from ITD
+ AML
samples contained the ITD insert revealing their leukemic
origin and, upon ex vivo culture with cytokines, they
acquired DC morphology. Notably, mDC/pDCs were
detectable concurrently with single lineage mDCs and
pDCs in all ITD
+ AML (n=11) and ITD
− AML (n=12)
samples analyzed for mixed lineage DCs (Lin
−, HLA-DR
+,
CD11c
+, CD123
+). ITD
+ AML mDCs/pDCs could be only
partially activated with CD40L and CpG for production of
IFN-α, TNF-α, and IL-1α, which may affect the anti-
leukemia immune surveillance in the course of disease
progression.
Keywords Acute myeloid leukemia.Dendritic cells.Flt3
ITD (FMS like tyrosine kinase internal tandem duplication)
Introduction
Dendritic cells (DCs) are professional antigen-presenting
cells (APCs) derived from bone marrow precursors. DCs
internalize and process antigens for presentation to T and B
cells in the lymphatic tissue for induction of adaptive
cellular and humoral responses. There are two major
subpopulations of DCs in the human peripheral blood,
CD11c
+CD123
− (mDC, also known as myeloid DC or
DC1) and CD11c
−CD123
+ DC (known as plasmacytoid
DC, pDC, or also DC2). DCs occur in very low frequency
in the peripheral blood of both humans and mice (<1%) [1],
and the homeostatic mechanism regulating DC frequency
has not been fully elucidated. It is established that DC
progenitors require factors such as granulocyte–macro-
phage colony-stimulating factor (GM-CSF: mDC) and
FMS-like tyrosine kinase 3 ligand (FL: mDC, pDC) to
expand and differentiate [2, 3]. FL is proposed to be a key
regulator of the DC compartment as it is expressed on early
hematopoietic stem and progenitor cells, particularly DC
precursors [4, 5]. Therefore, the exposure of myeloid and
lymphoid committed precursors to soluble FL can dramat-
ically increase mDC and pDC frequencies in mice and
humans [4, 6].
FLT3, the cognate FL receptor, is a frequent target for
mutations in leukemia. An internal tandem duplication
(ITD) mutation within FLT3 is found in approximately 30%
of acute myeloid leukemia (AML) cases with normal
M. Rickmann: J. Krauter:K. Stamer:M. Heuser: G. Salguero:
E. Mischak-Weissinger: A. Ganser:R. Stripecke
Department of Hematology, Hemostasis, Oncology and Stem Cell
Transplantation, Hannover Medical School (MH),
Hannover, Germany
R. Stripecke (*)
Lymphatic Cell Therapy Laboratory,
Hannover Medical School-OE6860,
Carl-Neuberg Str. 1,
30625 Hannover, Germany
e-mail: stripecke.renata@mh-hannover.de
Ann Hematol (2011) 90:1047–1058
DOI 10.1007/s00277-011-1231-2cytogenetics. The leukemic population is commonly mono-
clonal and its occurrence is linked with a particularly poor
prognosis and increased incidence of relapse [2, 7–10]. A
hallmark of FLT3-ITD
+ AML blasts is a constitutive
activation of the tyrosine kinase, leading to prolonged
survival and promoted proliferation of hematopoietic stem/
progenitor cells (independent of FL), as well as a partially
blocked differentiation along the granulocytic/monocytic
lineages [2, 5, 7, 11]. FLT3-ITD seems to be preferentially
associated with myelomonocytic and monocytic leukemia
(M4, M5) [12]. Although some DC markers have been
detected in FLT3-ITD
+ AML cells (HLA-DR, CD123,
CD4) [9], the association of FLT3-ITD
+ with abnormal
frequencies of mDCs or pDCs has not been described
previously in humans. Attempts to generate AML-DCs
using in vitro culture systems with cytokines have
previously indicated that FLT3-ITD would hamper the
differentiation of AML blasts towards dendritic cells [13],
but these studies did not specifically address the presence of
ITD
+ AML-DCs in the original diagnostic samples.
Incidentally, results obtained from murine bone marrow
transplantation assays demonstrated that a knock-in of an
ITD into murine FLT3 conferred myeloproliferative disease
with increment in the frequency of circulating and spleen
mDCs (CD11c
+, CD86
+)[ 14].
Since the characterization of DC frequencies in
clinical ITD
+ AML samples were not described before,
we examined whether the presence of the FLT3-ITD
mutation in diagnostic peripheral blood samples obtained
from AML patients would affect the occurrence of mDCs
and pDCs. Samples obtained from healthy donors and
ITD
− AML patients were used as a comparative parameter.
Here, we demonstrate that at leukemia presentation, FLT3-
ITD
+ AML patients and FLT3-ITD
− AML patients have a
conspicuously high frequency of circulating mDCs, pDCs,
and also mixed lineage mDCs/pDCs. Mixed lineage
mDCs/pDCs detected in FLT3-ITD
+ AML samples could
only be partially activated in vitro to produce inflamma-
tory cytokines.
Materials and methods
Patient samples
The collection of peripheral blood samples from healthy
volunteers (n=10) and AML patients was approved by the
local ethics committee of the Hannover Medical School
(MHH) and were obtained after an informed consent. A
total of 40 FLT3-ITD
+ and 47 FLT3-ITD
− AML patients
were included in the study (Table 1). Due to limitations on
the number of viable cells present in diagnostic leukemia
samples required for more complex flow cytometry
analyses (detection of mixed lineage DCs and analyses of
cytokine production), an additional second cohort was
included in the study, corresponding to 11 FLT3-ITD
+
patients and 12 FLT3-ITD
− patients (Table 1).
Cytogenetics and FLT3-ITD analyses
Cytogenetic and molecular genetic studies were performed
by the German–Austrian Acute Myeloid Leukemia Study
Group at Hannover Medical School or at the University of
Ulm. Blood diagnostic samples were analyzed for the
presence of ITD mutations in the FLT3 gene by polymerase
chain reaction as described previously [15]. For FLT3-ITD
molecular analyses, DNA was extracted from approximate-
ly 5×10
6 cells using Qiagen Blood Mini Columns accord-
ing to the protocol of the manufacturer. Polymerase chain
reaction (PCR) was performed with genomic DNA using
primer molecules FLT3-14f-6F 5′-GCA ATT TAG GTA
TGA AAG CCA GC-3′ and FLT3-E15R 5′-CTT TCA
GCA TTT TGA CGG CAA CC. A 5-ng DNA was
amplified in a total volume of 50 μl containing 50 mM
KCl, 10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl2 and 0.001%
(w/v) gelatine, 200 μM dNTPs, primer oligonucleotides
(FLT3-E14-6F [5-prime labeled with 6-FAM] and FLT3-
E5R; 0.5 μM each), and 1 unit of AmpliTaq Gold DNA
polymerase (Perkin-Elmer, Norwalk, CO, USA). The PCR
consisted of an initial incubation step at 95°C for 11 min
followed by 27 cycles at 94°C for 30 s, 57°C for 60 s, and
72°C for 120 s, and a final elongation step at 94°C for 30 s,
and 60°C for 45 min in ABI 9700 PCR machines. The PCR
products were resolved on a 2% agarose gels stained with
ethidium bromide. DNA of fluorescence-activated cell
sorting (FACS)-sorted cells with DC immunophenotype
was amplified by PCR and sequencing was performed on
an Applied Biosystems 3130 sequencer and analysed with
GeneMapper 4.0 (Applied Biosystems, Delaware/US).
Immunophenotypic analyses and sorting of mDCs
and pDCs
Peripheral blood mononuclear cells (PBMCs) obtained
from patients and healthy volunteers were isolated by
standard density gradient centrifugation using Ficoll (Bio-
coll separating solution, Greiner, Bio-One, Germany)
separation and cryopreserved in 90% FBS and 10% DMSO.
The mDCs and pDCs were identified using a commercially
available kit (“peripheral blood dendritic cell detection by
flow cytometry”, Becton Dickinson BD, San Jose, CA,
USA). The protocol is based on a four color staining. For
detection of myeloid DCs, we used lineage cocktail 1
(FITC) containing monoclonal antibodies (mABs) against
CD3, CD14, CD16, CD19, CD20, and CD56 as a negative
selection, a mAB against CD11c (APC, clone S-HCL-3), a
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against CD86 (clone FUN-1) or CD83 (clone HB15e) (both
PE). Detection of plasmacytoid DCs was similar, except that
instead CD11c, CD123 detection (PE, clone 9F5) was
performed. Stained cells were analyzed on a FACSCalibur
cytometerusingCellQuestsoftware(BD,SanJose,CA,USA).
Fifty thousand viable cells gated on the FSC/SSC scatter
were negatively selected using the lineage markers. The
resulting lin
− population was analyzed for HLA-DR/CD11c-
(mDCs) or HLA-DR/CD123- (pDCs) expressing cells. The
activation/maturation status of DCs was evaluated by
analyses of CD86 and CD83 expression.
Eleven additional ITD
+ AML samples for which we
could obtain higher viable cell numbers were further
characterized as mixed lineage mDCs and pDCs upon
analyses of lin
−/HLA-DR
+/CD11c
+/CD123
+ cells. Four of
the 11 patients were analyzed with an analysis based on
lin
−/HLA-DR
+/CD4
+/CD11c
+/CD123
+.T h es a m p l e sw e r e
incubated for 2 h with Golgi Plug (BD, Heidelberg) to
inhibit cytokine secretion. Cells were prepared following a
BD cytofix/cytoperm protocol for intracellular staining.
The cells were harvested on ice, washed, and stained for
the expression of cell surface lineage markers (FITC),
HLA-DR (V450, BD), CD11c (APC, BD), CD123 (PerCp
Cy-5.5, BD), and CD4 (Alexa700, BD). The cells were
subsequently stained intracellularly for tumor necrosis
factor (TNF)-α (PE-Cy 7) and INF-α (PE-Green A, BD)
or IL-1α (PE-Green A, BD), respectively. After staining,
cells were acquired at a minimum of 100,000 events. Five
color flow cytometry analysis was performed using an
LSR II apparatus. Analyses were made with BD FACS
DIVA.
Morphological analyses of thawed/sorted and ex vivo
cultured samples
In order to analyze the morphology of cells with mDC
or pDC immunophenotypes, diagnostic samples from six
Table 1 Patients’ characteristics for the first cohort (mDCs or pDCs analyses) and second cohort (mDCs or pDCs or mDC/pDC analyses)
(p≤0.05)
First cohort FLT3
ITD positive (N=33)
First cohort FLT3
ITD negative (N=42)
p value Second cohort FLT3
ITD positive (n=11)
a
Second cohort FLT3
ITD negative (n=12)
b
Age, median (range) years 62 (32–84) 56.5 (18–82) 0.17 60.38 (44–83) 56.8 (35–79)
Sex (no./%)
Male 18 (55) 25 (60) 0.67 6 (54) 6 (60)
Female 15 (45) 17 (40) 5 (46) 4 (40)
WBC median (×10
9/L) 95.19 65.69 0.1 67.7 63.52
FAB (no./%) N=18 N=21 0.29 N=10 N=8
M0 2 (11) 2 (10) 1 (9) 0 (0)
M1 1 (6) 5 (24) 2 (18) 2 (16)
M2 4 (22) 3 (14) 1 (9) 0 (10)
M3 3 (17) 0 (0) 0 (0) 0 (0)
M4 3 (17) 5 (24) 3 (27) 3 (25)
M5 5 (27) 6 (28) 5 (45) 3 (25)
Not FAB classified (15) (21) (1) (4)
Cytogenetics (no./%)
Favorable 3 (9) 3 (7) 0.13 0 (0) 0 (0)
Intermediate 26 (79) 28 (67) 7 (63) 7 (58)
Adverse 2 (6) 10 (24) 2 (18) 4 (33)
Missing 2 (6) 1 (2) 2 (15) 1 (10)
Probability of relapse (%) 15 24 0.51 N.A. N.A.
Allo-transplantation (%) 21 31 0.33 36 33
Complete remission
to date (CR) (no./%)
15 (45) 22 (54) 0.48 4 (36) 9 (75)
FAB French–American–British classification, FLT3 FMS-like tyrosine kinase 3, ITD internal tandem duplication, WBC white blood cells, N.A. not
applicable
aFour of the patients in this cohort were previously included in FLT3-ITD + cohort 1
bSeven of the patients in this cohort were previously included in FLT3-ITD- cohort 1
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+ patients were thawed and sorted for lin
−CD11-
c
+HLA-DR
+ (mDCs) and lin
−CD123
+HLA-DR
+ (pDCs)
o naF A C S A r i a( B D ) .C e l l sw e r ea n a l y z e dd i r e c t l ya f t e r
sorting by cytospin, Giemsa staining, and microscopy
(Olympus CKX 41) or were further cultivated under DC
differentiation/ maturation conditions. ITD
+ mDC-sorted
cells were cultured in 12-well culture plates in an X-vivo
medium (Lonza, Basel, Switzerland) in the presence of
recombinant human (rh) GM-CSF (20 ng/μl, Cell Genix
GmbH, Freiburg, Germany) and recombinant human (rh)
interleukin (IL)-4 (20 ng/μl, Cell Genix GmbH, Freiburg,
Germany). ITD
+ pDC-sorted cells were cultured in the
presence of rhIL-3 (10 ng/ml, R&D systems, Cologne,
Germany). After 5 to 7 days in culture, mDCs and pDCs
were stimulated with rhCD40- l i g a n d( C D 4 0 L )( 5 0n g / m l ,
R&D Systems, Cologne, Germany).
Results and discussion
ITD negative and positive AML samples show elevated
frequencies of mDCs and pDCs
We used a commercially available analytical procedure for
quantification of DC subsets in whole blood PBMC. CD3
−,
CD14
−, CD16
−, CD19
−, CD20
−, and CD56
- cells were
analyzed for expression of HLA-DR/CD11c (mDCs) or
HLA-DR/CD123 (pDCs) (Fig. 1a). Activated and matured
DCs were further characterized through analyses of CD86
and CD83 expression, respectively [1]. In order to validate
the methodology for DC frequency analyses in a healthy
control group, we initially analyzed the frequency of mDCs
and pDCs in fresh and cryopreserved samples obtained
from ten healthy volunteers (Fig. 1b). The fresh samples
were analyzed on the day of blood draw, whereas the
cryopreserved samples were maintained frozen for at
least 1 week prior to analysis. Although the numbers of
detectable mDCs (lin
−/CD11c
+/HLA-DR
+) and pDCs
(lin
−/CD123
+/HLA-DR
+) in cryopreserved samples were
lower than fresh samples, the difference was found not to
be statistically significant (Fig. 1b). Cryopreserved mDCs
of healthy volunteers (0.82±0.23% of PBMC) contained
mainly activated (CD86
+)a n dm a t u r e( C D 8 3
+)c e l l s .I n
contrast, in pDCs (0.44±0.19 of PBMC), only approxi-
mately half of the cells were activated and mature
(Fig. 1c). In contrast to the homogeneous frequencies of
the mDCs (in the range between 0.4% and 1.2%) and
pDCs (0.3–0.8%) in the PBMC obtained from healthy
volunteers, extremely variable frequencies of mDCs (0.3–
60%) and pDCs (0.2–70%) were observed in AML
Fig. 1 Experimental design and
validation of methods. a Schema
of the flow cytometry analyses
for detection of mDCs and
pDCs. b Frequencies of DCs
detectable in fresh (black)
versus thawed (grey) PBMCs
obtained from healthy donors
(n=10) do not differ signifi-
cantly (p values of mDCs,
0.15; pDCs, 0.44.). c Frequen-
cies of cells with mDC and pDC
immunophenotypes as total cells
or with additional expression of
the activation marker CD86 and
maturation marker CD83
(numbers indicate the average
and standard deviation for each
analyses; n=10)
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+ and ITD
− patients
(Fig. 2a, b).
Due to the high variability in the frequencies of cells
with mDC immunophenotype, we considered an “aber-
rant” mDC frequency for those samples showing mDC
frequencies equal or greater than 10% of the total viable
cells included in the analyses (thus, roughly
corresponding to tenfold higher than the normal mDC
frequency observed in healthy controls). A remarkable
proportion of AML samples had an “aberrant” mDC
frequency (42% for ITD
+ and 38% for ITD
−). We did not
observe significant differences between the distributions
of activated and matured mDCs in ITD
+ and ITD
−
samples (Fig. 2a). Nevertheless, what was noticeable in
these AML samples in comparison to the samples of
healthy volunteers, was that a much smaller fraction of
the AML-mDCs co-expressed CD86 or CD83, indicating
a lower activation and maturation status, respectively.
The average frequency of cells with pDC immunophe-
notype was also dramatically increased in AML diagnostic
samples compared to healthy controls (Fig. 2b). To
facilitate the analyses of the highly variable pDC frequen-
Fig. 2 Flow cytometry analyses
of cells with DC immunophe-
notype in AML diagnostic sam-
ples. a Frequencies of mDCs,
and b pDCs detected in
FLT3-ITD
+ (upper graphs)
and FLT3-ITD
- AML samples
(lower graphs). All analyses
indicated significantly higher
frequencies of mDCs and pDCs
in ITD
+ and ITD
− AML samples
in comparison with DCs analy-
ses in healthy subjects (p<0.05).
The panels on the right side
show representative FACS
analyses samples with the gating
strategy
Ann Hematol (2011) 90:1047–1058 1051cies, we considered “aberrant” the samples with equal or
greater than 2% frequency of pDCs (thus, more than
fivefold higher than healthy controls). Approximately,
40% of the samples analyzed in the ITD
+ group and
26% in the ITD
− group were classified as “aberrant”,
indicating an overall trend for high accumulation of pDCs.
Mohty et al. previously reported the aberrant fre-
quencies of DCs in cryopreserved AML samples [16].
In their work, however, samples were not stratified
according to the presence of FLT3-ITD and they used
immunoglobulin-like transcript 3 instead of HLA-DR as
co-expressed DC marker. In view of our current results,
ITD
+ AML samples seem to demonstrate an even more
pronounced pattern of aberrant DC frequencies than ITD
−
AML samples.
ITD negative and positive DCs detected in AML samples
show downregulation of HLA-DR
Expression of HLA-DR (corresponding to the major
histocompatibility complex II) in DCs detected in AML
diagnostic samples was expressed at significantly lower
levels than for DCs analyzed in the samples of healthy
controls (Fig. 3), a finding that correlates with previous
observations regarding the downregulation of HLA-DR in
AML samples obtained from ITD
+ patients [17, 18].
Notably, within the AML groups, the expression of
HLA-DR in DC populations detectable in ITD
+ AML
was significantly lower than in DCs detectable in ITD
−
samples (Fig. 3). The profound downregulation of HLA-
DR in ITD
+ DC subsets might be implicated in defective
class II antigen presentation leading to dysregulation of
these APCs. This could potentially affect presentation of
leukemia antigens to CD4
+ T helper cells, hampering
development of a stimulatory cytokine environment for
anti-leukemia immune responses.
mDCs and pDCs detectable in ITD
+ AML samples
are derived from leukemia and can be driven
to further differentiate morphologically with cytokines
in vitro
An important observation by Mohty et al. [16], who had
previously reported high frequencies of mDC and pDC
subsets in diagnostic AML samples, was that these cells
were likely of leukemic origin since they carried the same
translocations as the original leukemia. In order to extend
this observation to ITD
+ leukemia, DCs obtained from
three different ITD
+ AML samples were sorted and
examined for the presence of the ITD by PCR. DCs sorted
from the ITD
+ AML samples contained the ITD mutation,
demonstrating that they originated from leukemic blasts
(Fig. 4).
These ITD
+-sorted DCs were then used for cytospin/
Giemsa preparations and morphological analyses (Fig. 5).
Sorted mDCs (Lin
−,H L A - D R
+,C D 1 1 c
+) corresponded to
cells with appearance of monocytic blasts with high
nuclear-to-cytoplasmic ratio (Fig. 5a). Sorted pDCs
demonstrated blast-like morphology with some cells
resembling the normal pDC morphology originally de-
s c r i b e db yS i e g a le ta l .[ 19] and some presenting the
“AML-cuplike” description of Kussick et al. [18], who
previously described FLT3-ITD
+ blasts with prominent
nuclear invagination and decreased HLA-DR expression
(Fig. 5b). Sorted ITD
+ DCs that could be cultured ex vivo
in the presence of cytokines commonly used for terminal
differentiation of mDCs (GM-CSF, IL-4, CD40L) or
pDCs (IL-3, CD40L) were analyzed. ITD
+ mDCs main-
tained in the presence of GM-CSF/IL-4 for 5 days
resulted in a population of large cells with dendrites,
and upon subsequent 24-h treatment with CD40L,
abundant veils on the cell surface typical of mDCs were
observed (Fig. 5c). Sorted ITD
+ pDCs cultured in the
presence of IL-3 for 5 days resulted in conspicuously
large cells, and subsequent 24-h treatment with CD40L
resulted in cells with high granularity (Fig. 5d). Put
together, these results demonstrated that circulating ITD
+
DCs have characteristics of leukemic blasts, which upon
ex vivo, supra-physiological stimulation with cytokines
Fig. 3 Flow cytometry analyses of HLA-DR expression in AML
cells. a Mean fluorescence intensity (M.F.I.) of HLA-DR expression
on mDCs showing significant (asterisk) differences in the expression
level comparing healthy (n=10), ITD
− (n=42) and ITD
+ (n=33)
PBMC. b M.F.I. of HLA-DR expression on pDCs
1052 Ann Hematol (2011) 90:1047–1058Fig. 4 Sequencing of PCR-ITD
mutational insert product from
ITD
+ patients. In addition to the
w.t. FLT3 amplification product,
the ITD mutational insert is
detectable in the original AML
patient samples and in the sorted
DCs
Fig. 5 Morphological analyses of cytospin/Giemsa preparations of
FLT3-ITD
+ AML diagnostic samples prior and post-sorting of mDCs
and pDCs. AML samples obtained from three patients and containing
high frequencies of mDCs (a)o rp D C s( b) before and after sorting
resemble leukemia blasts. c ITD
+ AML-mDCs after sorting and culture
with GM-CSF/IL-4 and maturation with CD40L show cell enlargement
and veils. d ITD
+ AML pDCs after sorting and culture with IL-3 and
maturation with CD40L show cell enlargement and high granularity
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more differentiated characteristics.
General occurrence of a mixed lineage population of mDCs
(CD11c
+)/pDCs (CD123
+)i nI T D
+ and ITD
− AML samples
Previous work describing the occurrence of high frequencies
of DCs in AML samples considered the CD11c
+ mDC and
CD123
+ pDC populations as mutually exclusive events [16].
Since we had observed that some AML samples had high
frequencies of both mDCs and pDCs and since the
expression of markers of various hematopoietic lineages is
common in leukemogenesis, we evaluated whether mixed
mDCs/pDCs lineages could also be found in ITD
+ and/or
ITD
− AML samples. The subsequent flow cytometry
analyses consisted in the negative selection of non-DC
lineage markers, positive selection of HLA-DR
+ DCs and,
within this defined DC population, we analyzed the
frequencies of single or double CD11c
+ and CD123
+ cells
(Fig. 6a). For a subset of ITD
+ patients, we also included the
selection of CD4
+ cells for a more stringent characterization
of DCs (three representative examples are shown in Fig. 7).
Surprisingly, double positive mDC/pDC populations
were observed in all ITD
+ and ITD
− AML samples
analyzed, and the frequency of double positive DCs
corresponded to an average of 58% for ITD
+ and 67% of
ITD
−, indicating their preponderance (Fig. 6b,T a b l e s2
and 3). In addition to the double positive mDCs/pDCs,
single mDCs and pDCs cell populations were also
detectable in the samples in different distributions
(Tables 2 and 3 A–C). Of note, CD11c
+/CD123
+ cells
have recently been described as early precursors of
myelocytic DCs derived from CD34
+ progenitors [20–
22]. In fact, CD123 is the IL-3 receptor (IL-3R) alpha
chain, which is a well-established stem cell marker in
healthy and leukemic CD34
+ stem cells, and is known to
be downregulated only late in myeloid differentiation.[23–
25]. IL-3R/ CD123 expression in ITD
+ AML blasts has
been described as a frequent event [26, 27], which here
seems to be associated with the accumulation of DC
precursors that are not terminally differentiated towards
mDC or pDC. Of note, in this study, we also observed that
as u b s e to fI T D
+ AML samples showed a significantly
higher expression of CD123 when compared with ITD
−
AML samples (data not shown).
Analogous to our findings, Ma et al. [28] have also
demonstrated clonal involvement in circulating myeloid
and lymphoid precursors of dendritic cells in peripheral
blood of patients with myelodysplastic syndromes. Alto-
gether, these observations provide evidence that ITD
+ and
also ITD
− leukemic or progenitor stem cells differentiate
towards common CD11c
+/CD123
+ mDC/pDC precursors
which are accumulated prior to subsequent split between
differentiated mDCs and pDCs.
Stimulation of mDCs/pDCs with CD40L or CpG results
into partial activation of the cells for production
of inflammatory cytokines
ITD
+ AML samples were further analyzed for mDC/pDC
frequencies based on detection of the surface markers Lin
−/
HLA-DR
+/CD4
+. Using these more stringent analyses, 5.2–
20.5% of the DCs present in the ITD
+ AML samples
corresponded to mDC/pDCs (Fig. 7a).
In order to correlate the immunophenotypic character-
istics of the mDC/pDC mixed lineage population with DC
function, we performed intracellular staining of inflamma-
tory cytokines [interferon (IFN)-α, TNF-α,I L - 1 α] after
stimulation of the AML blasts with CD40L or CpG
(Fig. 7b). We used healthy donors as controls for these
analyses, which confirmed upregulation of IFN-α produc-
tion by pDCs after CpG stimulation (Fig. 7). IFN-α and IL-
1α were detectable in all mDC/pDC populations, but their
regulation through CpG and CD40L was extremely
variable. Production of TNF-α by mDCs/pDCs was hardly
detectable in comparison to healthy mDCs and pDCs
Fig. 6 Immunophenotypic detection of mDCs/pDCs’ mixed lineages.
a Schematic presentation of flow cytometry analyses. b Average
frequency of mixed lineage mDCs/pDCs, single mDCs and pDCs
obtained for ITD
+ and ITD
− patients
1054 Ann Hematol (2011) 90:1047–1058(Fig. 7). Thus, these functional analyses indicated a
deregulated baseline cytokine production and stimulatory
responses in mDCs/pDCs.
Based on long-standing clinical expertise that graft
versus leukemia (GVL) effect is an immunologic factor
positively influencing leukemia eradication, immunothera-
peutic approaches to enhance GVL have been sought.
During past years, several groups have pointed to the fact
that AML cells can express antigens and can be “corrected”
as antigen-presenting cells through cytokine stimulation
leading to their terminal differentiation [29]. This approach
was however not shown practical for ITD
+ AML cultures
maintained in vitro, which failed to generate ITD
+ AML-
DCs in the presence of GM-CSF, IL-4, and TNF-α [13]. In
our work, we did obtain a partial correction of the DC
morphology and cytokine production, but this was mainly
noticeable in the presence of CD40L or CpG, which drive
terminal maturation of DCs.
In summary, our work demonstrates that both ITD
+
and ITD
− AML samples contain a high proportion of cells
with DC progenitor characteristics, hindered in terminal
differentiation, partially blocked for maturation, and with
deregulated cytokine production characteristics. Thus, our
study indicates immunosuppressive mechanisms of an
immature mDC/pDC leukemic lineage, which might be
operative during leukemogenesis and can potentially
Fig. 7 Functional analyses of double positive CD11c/CD123 mDCs/pDCs in ITD
+ AML samples of three patients. a Gating approach for
detection of mDCs/pDCs. b Frequency of mDC/pDCs with detectable intracellular cytokines after stimulation with CD40L or CpG
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immune escape of leukemia cells.
These results suggest that by hindering the “AML-DC”
differentiation and maturation, the occurrence of FLT3-ITD
can potentially undermine anti-leukemia immune responses,
which calls for more effective adjuvant immunotherapeutic
strategies in ITD
+ leukemia in order to rebound the immune
regeneration for ultimate leukemia elimination.
Table 3 Frequency of double positive mDCs/pDCs and single mDCs and pDCs in 12 ITD
− AML samples
AML sample WBC FAB % DCs in PBMC % mDC/pDC in DCs % mDC in DCs % pDC in DCs
A: High mDC/pDC and high mDC frequencies
1 4.7 M1 58.26 36.09 57.57 6.32
2 182 N.A. 9.9 87.36 10.20 2.41
3 76 M4 9.15 59.22 34.09 6.67
B: High mDC/pDC and high pDC frequencies
4 5.2 N.A. 8.11 81.37 3.33 15.29
5 34 M5b 53.71 71.37 0.36 28.23
6 6.8 M4 27.44 58.71 1.75 39.54
7 129.5 N.A. 52.79 61.53 1.52 36.94
C: High mDC/pDC and high mDCs or pDCs
8 0.7 M4eo 23.97 60.52 18.22 21.23
9 69 N.A. 31.8 62.33 18.21 19.47
10 18.4 M5 21.97 61.63 15.66 22.70
11 23.2 M1 8.08 77.60 13.24 9.16
12 115.7 M5 1.57 82.17 7.01 10.83
The samples varied relative to the majority of mDCs (A), pDCs (B), but for most of the cases comparable frequencies of mDCs and pDCs were
observed (C)
AML acute myeloid leukemia, FAB French–American–British classification, WBC white blood cells, N.A. not applicable, DCs dendritic cells,
PBMC peripheral blood mononuclear cell, pDC plasmacytoid dendritic cell, mDC myeloid dendritic cell
Table 2 Frequency of double positive mDCs/pDCs and single mDCs and pDCs in 11 ITD
+ AML samples
AML sample WBC FAB % DCs in PBMC % mDC/pDC in DCs % mDC in DCs % pDC in DCs
A: High mDC/pDC and high mDC frequencies
5 6.3 M4 23.28 79.30 18.17 2.53
6 56.2 M5a 39.2 34.95 64.79 0.25
7 30.3 M4/5 34.7 64.54 30.84 4.61
8 216 M0 34.1 39.00 60.41 0.59
9 107 M5a 39.1 69.80 29.92 0.25
10 1.5 M1 3.57 27.74 60.50 11.76
B: High mDC/pDC and high pDC frequencies
1 69.9 M2 39.04 35.00 0.48 64.52
2 46.3 M5 52.02 64.28 6.62 29.10
11 65.5 M5 11.00 73.09 8.09 18.82
4 79.0 N.A. 11.55 55.16 10.32 34.52
C: High mDC/pDC and low mDCs or pDCs
3 66.7 M5 45.97 90.12 5.21 4.67
Despite the fact that mDCs/ pDCs were observed in all AML samples, most of the samples showed high frequency of mDCs (A), and some
samples showed also high frequencies of pDCs (B) or comparable frequencies of mDCs and pDCs (C)
AML acute myeloid leukemia, FAB French–American–British classification, FLT3 FMS-like tyrosine kinase 3, ITD internal tandem duplication,
WBC white blood cells, N.A. not applicable, PBMC peripheral blood mononuclear cell, DCs dendritic cells, pDC plasmacytoid dendritic cell,
mDC myeloid dendritic cell
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